Olvi-Vec: Lead clinical candidate Olvi-Vec is a modified form of the oncolytic vaccinia virus; Genelux is actively recruiting patients in our OnPrime Phase 3 clinical trial for the treatment of platinum-resistant/refractory ovarian cancer

Why Oncolytic Immunotherapy?

Oncolytic immunotherapy is an immunotherapy modality where viruses selectively replicate and kill tumor cells while leaving normal cells intact.


Viral cell killing has the potential to expose all the tumor’s neoantigens to the immune system and to establish long-term antitumor immunity to improve outcomes for cancer patients.

Our Approach

We utilize vaccinia virus (VACV) as the backbone of our therapeutics and diagnostics platform. VACV has a number of characteristics which we consider desirable in an oncolytic virus for clinical applications:


  • No genomic integration
  • Highly modular and customizable
  • Broad spectrum of activity
  • Robust lytic capabilities and high replication and proliferation
  • Powerful immune activator (Th1-type immune response)


The CHOICE™ discovery platform is the proprietary foundation of our oncolytic immunotherapy product development program and allows us to rapidly generate new product candidates from conception through the initiation of clinical trials. CHOICE™ has produced more than 500 different versions of the vaccinia virus armed with more than 110 transgenes, and has a variety of engineered attributes, including immune modulatory and cell killing properties.

The OLVI-VEC difference:

BELIEVED TO BE THE MOST ADVANCED clinical development program involving non-local delivery oncolytic virus

    • Actively recruiting patients for our registrational OnPrime Phase 3 clinical trial in platinum-resistant/refractory ovarian cancer
    • Actively preparing for Phase 2 trial in recurrent non-small cell lung cancer
    • Demonstrated antitumor activity as monotherapy and combination therapy


VERSATILE AND PERSONAL potential utility in multiple additional clinical settings

    • Physician-preferred/familiar route(s) of administration: early-stage clinical trials in solid tumors supports intravenous systemic administration
    • Potential against difficult-to-treat solid tumors and metastatic disease, and liquid tumors
    • Large-scale manufacturing process produces “off-the-shelf” therapeutic eliciting patient-specific immune responses
Genelux vision
Genelux Leadership
Genelux newsroom

“We believe Olvi-Vec will add an important weapon to the medical armamentarium in the fight against the most difficult-to-treat cancers.”

-Thomas Zindrick, JD, President. Chief Executive Officer and Chairman